We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: One dose of antibiotic treats early syphilis in addition to three doses, medical trial reveals
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Health > One dose of antibiotic treats early syphilis in addition to three doses, medical trial reveals
One dose of antibiotic treats early syphilis in addition to three doses, medical trial reveals
Health

One dose of antibiotic treats early syphilis in addition to three doses, medical trial reveals

Last updated: September 4, 2025 1:24 am
Editorial Board Published September 4, 2025
Share
SHARE

Credit score: Unsplash/CC0 Public Area

Researchers have discovered {that a} single injection of the antibiotic benzathine penicillin G (BPG) efficiently handled early syphilis simply in addition to the three-injection routine utilized by many clinicians in the US and elsewhere. These findings from a late-stage medical trial counsel the second and third doses of standard BPG remedy don’t present a well being profit.

The outcomes are revealed within the New England Journal of Medication.

“Benzathine penicillin G is highly effective against syphilis, but the three-dose regimen can be burdensome and deter people from attending follow-up visits with their health care providers,” mentioned Carolyn Deal, Ph.D., chief of the enteric and sexually transmitted infections department of NIH’s Nationwide Institute of Allergy and Infectious Illnesses (NIAID).

“The new findings offer welcome evidence for potentially simplifying treatment with an equally effective one-dose regimen, particularly while syphilis rates remain alarmingly high.”

Syphilis is a standard sexually transmitted an infection (STI) attributable to the bacterium Treponema pallidum. America reported 209,253 whole syphilis instances and three,882 congenital syphilis instances in 2023, representing 61% and 108% will increase over 2019 numbers, respectively.

With out therapy, syphilis can lead to neurological and organ harm in addition to extreme being pregnant issues and congenital abnormalities. Syphilis may improve an individual’s chance of buying or transmitting HIV.

BPG is among the few antibiotics identified to successfully deal with syphilis, and stockouts are widespread worldwide. The antibiotic is presently being imported to the US to resolve a nationwide scarcity.

The research was carried out at 10 U.S. websites and enrolled 249 contributors with early syphilis, which encompasses the first, secondary, and early latent phases of illness; 61% of contributors have been dwelling with HIV and 97% have been males.

The contributors have been randomly assigned to obtain both a single intramuscular (IM) injection of BPG 2.4 million items (MU) or a sequence of three IM injections of BPG 2.4 MU at weekly intervals. All contributors have been monitored for security. Organic markers of profitable therapy within the blood—often called the serologic response to remedy—have been examined at six months following therapy.

Some 76% of contributors within the single-dose group had a serologic response to therapy in comparison with 70% of contributors within the three-dose group. The distinction between teams was not statistically vital, even when contributors have been stratified by HIV standing.

One participant developed indicators of neurosyphilis three days after beginning BPG remedy and was excluded from the evaluation. Three critical antagonistic occasions have been reported however weren’t associated to BPG.

“Syphilis has been studied and treated for more than a century, and BPG has been in use for more than 50 years, yet we are still acquiring knowledge to help us optimize treatment,” mentioned Principal Investigator Edward W. Hook III, M.D., emeritus professor of drugs and epidemiology on the College of Alabama at Birmingham.

“We hope these promising results will be complemented by scientific advances in syphilis prevention and diagnosis.”

Based on the research authors, the outcomes from this trial present substantial proof that single-dose BPG 2.4 MU is as efficient as three doses in treating early syphilis. Extra analysis is required to know the total potential of this abbreviated therapy technique and to guage therapeutic approaches for all phases of syphilis, together with late syphilis, latent syphilis of unknown period, and medical neurosyphilis.

The research was carried out by way of the Sexually Transmitted Infections Scientific Trials Group.

Extra data:
Benzathine penicillin G, 1 vs 3 weekly doses, for early syphilis therapy, New England Journal of Medication (2025). DOI: 10.1056/NEJMoa2401802

Supplied by
Nationwide Institutes of Well being

Quotation:
One dose of antibiotic treats early syphilis in addition to three doses, medical trial reveals (2025, September 3)
retrieved 3 September 2025
from https://medicalxpress.com/information/2025-09-dose-antibiotic-early-syphilis-doses.html

This doc is topic to copyright. Aside from any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for data functions solely.

You Might Also Like

Psilocybin may reverse results of mind accidents ensuing from intimate associate violence, rat research finds

Predicting illness outbreaks utilizing social media

Deep mind stimulation succeeds for 1 in 2 sufferers with treatment-resistant extreme melancholy and nervousness in trial

Australian drug driving deaths have surpassed drunk driving. Here is the way to deal with it

Tooth of infants of confused moms come out earlier, suggests examine

TAGGED:antibioticClinicaldosedosesEarlyshowsSyphilistreatstrial
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
Jill Biden’s White House Christmas Looks Very … Normal
Fashion

Jill Biden’s White House Christmas Looks Very … Normal

Editorial Board December 1, 2021
Common Studios Hollywood closed Wednesday resulting from L.A. fires
Are you able to promote a condemned home?
Yankees’ Devin Williams says reclaiming nearer’s function ‘doesn’t matter’ to him as zeros pile up
Integrating human and animal well being care will increase entry to companies for homeless youth

You Might Also Like

New malaria drug heralds resistance breakthrough
Health

New malaria drug heralds resistance breakthrough

November 18, 2025
Chasing a successful streak: A brand new approach to set off responses within the physique by simulating psychological strain
Health

Chasing a successful streak: A brand new approach to set off responses within the physique by simulating psychological strain

November 18, 2025
The worldwide system for assessing organ dysfunction in critically sick sufferers is up to date after thirty years
Health

The worldwide system for assessing organ dysfunction in critically sick sufferers is up to date after thirty years

November 18, 2025
Breast most cancers remedies can enhance each survival probabilities and revenue
Health

Breast most cancers remedies can enhance each survival probabilities and revenue

November 18, 2025

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • Art
  • World

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?